par INTRASENSE (EPA:ALINS)
INTRASENSE : DUOnco™ Pancreas CE marking: a key innovation for the early detection of pancreactic cancer using AI
DUOnco™ Pancreas CE marking: a key innovation for the early detection of pancreatic cancer using AI
Montpellier, France, 13 August 2025, 6:00pm. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), a French expert in AI-enhanced medical imaging solutions that facilitate diagnostics, decision-making, and therapeutic follow-up, announces the CE marking under MDR (Medical Device Regulation) for DUOnco™ Pancreas, marking a new milestone in its innovation strategy focused on oncology follow-up.
« With DUOnco™ Pancreas, we are providing radiologists with a solution designed to facilitate the identification of pancreatic lesions at an early stage. This innovation reflects our commitment to developing AI tools that are useful in everyday clinical practice and patient care. This new CE marking reinforces our technological leadership and represents a further step in our expansion in France and internationally » says Alexandre Salvador, Intrasense’s CEO.
An AI solution serving diagnosis
Pancreatic cancer is particularly difficult to detect before it reaches an advanced stage. Currently below 10%[1], the fiveyear survival rate can triple to reach 30%[2], if the tumor is detected early, when it measures less than 2 cm.
 |
In this context, early detection of lesions is essential, and artificial intelligence can play a major role in improving patient prognosis. DUOnco™ Pancreas addresses this challenge by automatically analyzing CT images to highlight even subtle pancreatic lesions and by providing a precise segmentation of the main pancreatic duct. The solution prioritizes detected abnormalities into three levels defined by the physician, helping to direct the radiologist’s attention toward the most critical areas.
In practice, AI complements radiologists’ expertise. By drawing attention to areas that might not otherwise be examined - especially when there is no initial indication regarding the pancreas - it increases the likelihood of detecting incidental findings that could influence patient management.
A strategic step in the product strategy
Obtaining CE marking for DUOnco™ Pancreas is a major strategic milestone for Intrasense, enabling the clinical deployment of this solution in the European market in compliance with MDR (2017/745) regulations.
DUOnco™ Pancreas is part of the DUOnco™ product roadmap, co-developed with Guerbet, aimed at providing multiorgan AI solutions for early detection and oncology follow-up. Following solutions dedicated to the liver and bone lesions, the pancreas now becomes a new strategic component to expand AI’s role in oncology. This step confirms Intrasense’s ability to turn clinical needs into practical solutions valued by radiologists and aligned with public health priorities.
About Intrasense
A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group, Intrasense designs medical imaging software solutions natively enriched by artificial intelligence algorithms.
Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, optimizes and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers an AI for the detection of lesions in the liver, bones and pancreas. Liflow®, a dedicated oncology monitoring solution integrating multiorgan AI, optimizes the longitudinal monitoring of cancer patients.
By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high medical value tools, facilitating analysis, diagnosis and patient management. More information on www.intrasense.fr
Contacts
INTRASENSE Communication officer Salomé Sylvestre | SEITOSEI.ACTIFIN Analyst & Investor Relations Foucauld Charavay |
Phone : +33 4 67 13 01 30 Phone : +33 6 70 83 79 15
investisseurs@intrasense.fr intrasense@seitosei-actifin.com
Press Relations
Isabelle Dray
Phone : +33 6 85 36 85 11 isabelle.dray@seitosei-actifin.com
 |
Press release
[1] Drouillard, A., et al., [Epidemiology of pancreatic cancer]. Bull Cancer, 2018.
[2] Pongprasobchai S, Pannala R, Smyrk TC, Bamlet W, Pitchumoni S, Ougolkov A, de Andrade M, Petersen GM, Chari ST. Long-term survival and prognostic indicators in small (<or=2 cm) pancreatic cancer. Pancreatology. 2008.
Press release